Analysis of the Application Effect of Ranibizumab Monoclonal Antibody Combined with Compound Thrombus Capsules in Patients with Retinal Vein Occlusion
Objective To explore the application effect of ranibizumab monoclonal antibody combined with compound thrombus capsules in patients with retinal vein occlusion(RVO).Methods 66 RVO patients admitted to Fuming Hospital in Fan County,Puyang City,Henan Province from April 2021 to April 2022 were selected and randomly divided into a combination group(33 cases)and a control group(33 cases)according to the digital table method.The control group was treated with ranibizumab monoclonal antibody,and the combination group was given ranibizumab monoclonal antibody combined with compound thrombus capsules.The therapeutic effects,best corrected visual acuity level before and after treatment,retinal macular thickness,and recurrence situation of the two groups were compared.Results The effective rate of treatment in the combination group(96.97%)was higher than that in the control group(78.79%),and the difference was statistically significant(P＜0.05).The best corrected visual acuity level after treatment in both groups was higher than before treatment,and the combination group was higher than the control group,and the differences were statistically significant(P＜0.05).The retinal macular thickness after treatment in both groups was lower than before treatment,and the combination group was lower than the control group,and the differences were statistically significant(P＜0.05).The RVO recurrence rate in the combination group(3.03%)was lower than that in the control group(18.18%),and the difference was statistically significant(P＜0.05).Conclusion The treatment of RVO with ranibizumab monoclonal antibody combined with compound thrombus capsules has an ideal effect,which can help improve the best corrected visual acuity of patients,reduce retinal macular thickness,and RVO recurrence rate.
万方数据
维普
